Ra Pharmaceuticals was a Cambridge, Massachusetts-based clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics targeting the complement system to treat rare and severe diseases. The company's lead asset zilucoplan targeted generalized myasthenia gravis. Ra Pharmaceuticals was acquired by UCB for approximately $2.1 billion in April 2020.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountApr 2020
Oct 2016
Jul 2015
Jan 2012
Feb 2010
Create a free account to see which investors have funded this company.
Create Free Account
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Clinical-stage biopharma developing precision medicines for cancer and other serious diseases usi...
Biotech venture firm and therapeutics accelerator that invests at seed stage and acts as a drug d...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Uses AI to analyze natural chemistry and accelerate discovery of new medicines for biopharma and ...
